Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the updated safety and efficacy results of a Phase I trial (NCT04674813) investigating BMS-986393, a GPRC5D-targeted CAR T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Nadeem highlights that the agent shows high response rates of around 90% in the cohort of patients who have received one to three prior lines of therapy (LOT), with a significant proportion achieving complete responses and measurable residual disease (MRD) negativity. No new safety signals were observed. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
